Quantcast
Home > Quotes > ZEAL

Zealand Pharma A/S American Depositary Shares (ZEAL) Quote & Summary Data

ZEAL 
$21.1515
*  
0.5985
2.75%
Get ZEAL Alerts
*Delayed - data as of Aug. 16, 2019  -  Find a broker to begin trading ZEAL now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
29
Today's High / Low
$ 21.77 / $ 21.08
Share Volume
30,150
50 Day Avg. Daily Volume
12,813
Previous Close
$ 21.75
52 Week High / Low
$ 23.55 / $ 11.51
Market Cap
671,572,118
P/E Ratio
7.55
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ 2.80
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
2

Intraday Chart

Shares Traded

Share Volume:
30,150
50 Day Avg. Daily Volume:
12,813

P/E Ratio

P/E Ratio:
7.55
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ 2.80

Trading Range

The current last sale of $21.1515 is 83.77% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 21.77 $ 23.55
 Low: $ 21.08 $ 11.51

Company Description (as filed with the SEC)

We were founded in 1998 and are a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. We intend to be a leader in specialty medicines focusing on metabolic and gastrointestinal diseases and other specialty disease areas with significant unmet medical needs. Our current pipeline of internal product candidates focuses on specialty gastrointestinal and metabolic diseases. Our portfolio also includes two clinical license collaborations with Boehringer Ingelheim. Since 2003 we have had a license collaboration with Sanofi, or the Sanofi License Agreement, in the diabetes field pertaining to the development and commercialization of lixisenatide, both as a standalone therapy and as a combination therapy. Pursuant to the Sanofi License Agreement, we were entitled to receive certain royalties and commercial milestones in respect of global net-sales of Soliqua® 100/33/ Suliqua® and Lyxumia®/Adlyxin® .  ... More ...  



Risk Grade

Where does ZEAL fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 21.48
Open Date:
Aug. 16, 2019
Close Price:
$ 21.11
Close Date:
Aug. 16, 2019


Consensus Recommendation

Analyst Info